A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains

Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports

(2019) O. Lamy et al.   OSTEOPOROSIS INTERNATIONAL

Stopping Denosumab

(2019) Olivier Lamy et al.   Current Osteoporosis Reports

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Underestimation of Vertebral Fractures After Denosumab Discontinuation

(2018) Olivier Lamy et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

(2018) David W Dempster et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

New and emerging concepts in the use of denosumab for the treatment of osteoporosis

(2018) E. Michael Lewiecki   Therapeutic Advances in Musculoskeletal Disease

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

(2017) Athanasios D Anastasilakis et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

(2017) Panagiotis Anagnostis et al.   MATURITAS

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

(2017) B. Uebelhart et al.   OSTEOPOROSIS INTERNATIONAL

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

(2017) T. Lehmann et al.   OSTEOPOROSIS INTERNATIONAL

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

UK clinical guideline for the prevention and treatment of osteoporosis

(2017) J. Compston et al.   Archives of Osteoporosis

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016--EXECUTIVE SUMMARY

(2016) Pauline M. Camacho et al.   Endocrine Practice

Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report

(2016) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

(2015) B. Aubry-Rozier et al.   OSTEOPOROSIS INTERNATIONAL

Multiple clinical vertebral fractures following denosumab discontinuation

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE